Gufic BioSciences Quarterly Results for Trading Insights
In Sept 2025, Gufic BioSciences (GUFICBIO) reported revenue ₹239 Cr and net profit ₹17 Cr — revenue +17.2% YoY. Also explore GUFICBIO price trends to track price trends across different timeframes.
GUFICBIO Quarterly Results — Revenue, Profit & EPS Highlights
Gufic BioSciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Gufic BioSciences screener.
- Revenue of ₹239 Cr in Sept 2025 (+16.6% vs Mar 2025, +17.2% vs Sept 2024)
- Net Profit of ₹17 Cr in Sept 2025 (+112.5% vs Mar 2025, -22.7% vs Sept 2024)
- EBITDA of ₹40 Cr in Sept 2025 (+48.1% vs Mar 2025)
- Operating Margin of 16.0% in Sept 2025 (+3.0pp vs Mar 2025)
- Earnings Per Share of ₹1.68 in Sept 2025 (+118.2% vs Mar 2025)
Gufic BioSciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GUFICBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 239 | 205 | 225 | 232 | 204 | 16.6% | 17.2% |
| Net Profit (₹ Cr) | 17 | 8 | 13 | 12 | 22 | - | - |
| EBITDA (₹ Cr) | 40 | 27 | 34 | 34 | 39 | - | - |
| EPS (₹) | 1.68 | 0.77 | 1.30 | 1.24 | 2.17 | - | - |
| Operating Margin (%) | 16.0% | 13.0% | 15.0% | 14.0% | 19.0% | - | - |
GUFICBIO Share Price Trend — 1-Year Movement Across Quarterly Results
Gufic BioSciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with GUFICBIO DCF valuation to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GUFICBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gufic BioSciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1880.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 144.6 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6893.0 | 2,860 | 689 | +7.1% | - | 24.1% | 265.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4429.2 | 3,219 | 591 | +11.3% | - | 18.4% | 252.5 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1399.5 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.7 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1321.9 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 498.8 |
All amounts in ₹ Crores